Journal of Cardiac Failure
Volume 15, Issue 9 , Pages 790-797, November 2009

Percutaneous Implantation of an Intraventricular Device for the Treatment of Heart Failure: Experimental Results and Proof of Concept

  • Serjan D. Nikolic, PhD, FACC

      Affiliations

    • Cardiokinetix, Menlo Park, CA
    • Corresponding Author InformationReprint requests: Dr. Serjan D. Nikolic, CardioKinetix, Inc., Chief Technical Officer, 925 Hamilton Avenue, Menlo Park, CA 94025. Tel: (650) 364-7016; Fax: (650) 364-7038.
  • ,
  • Alex Khairkhahan, MS

      Affiliations

    • Cardiokinetix, Menlo Park, CA
  • ,
  • Miho Ryu, DVM

      Affiliations

    • BioSurg, Winters, CA
  • ,
  • Gerard Champsaur, MD, FACC

      Affiliations

    • Cardiokinetix, Menlo Park, CA
  • ,
  • Eugene Breznock, PhD, DVM

      Affiliations

    • BioSurg, Winters, CA
  • ,
  • Michael Dae, MD

      Affiliations

    • University of California, San Francisco, CA

Received 6 November 2008; received in revised form 23 March 2009; accepted 8 May 2009. published online 13 July 2009.

Abstract 

Background

A percutaneous system to implant a ventricular partitioning device (VPD) has been developed to partition the left ventricular (LV) cavity for treating regional wall motion abnormalities associated with post-left anterior descending (LAD) infarction, dilated left ventricle, and systolic dysfunction. The hemodynamic effects of this novel approach were evaluated in an ovine model with an anteroapical infarction created by a coil placed in the LAD.

Methods and Results

LV anteroapical infarction (MI) was induced in 10 animals. The VPD device was implanted at 6 weeks after MI in 5 animals. The hemodynamic status of each animal was evaluated at 30 weeks post-MI in treated (“VPD+MI” group, n=5) and nontreated (“MI” group, n=5). The comparison of end-point hemodynamic variables shows a significantly smaller end-systolic LV volume in the animals receiving the implant (70.1±9.0mL in “VPD+MI” group vs. 102.9±10.3mL in “MI” group, P < .02), improved ejection fraction (46.9±5.2% in “VPD+MI” group vs. 34.7±6.8% in “MI” group, P < .04) and preserved cardiac output (5.2±0.7 L/min in “VPD+MI” group vs. 5.0±1.8 L/min in “MI” group, P=NS), suggesting more efficient mechanical performance of the LV with the implanted VPD.

Conclusions

A significant reduction in LV volumes and corresponding improvement in LV function occurred after device implantation indicating a potential beneficial effect of this new device in treatment of post MI LV dilation.

Key Words: Myocardial infarction, left ventricular dilation, heart failure, intraventricular implant

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 S.D.N., A.K., and G.C. are employees of Cardiokinetix, Inc., the sponsor of this study. M.D. is consultant to Cardiokinetix, Inc.

PII: S1071-9164(09)00170-5

doi:10.1016/j.cardfail.2009.05.014

Refers to erratum:

  • Erratum

    Journal of Cardiac Failure December 2009 (Vol. 15, Issue 10, Page 939)

Journal of Cardiac Failure
Volume 15, Issue 9 , Pages 790-797, November 2009